Last reviewed · How we verify
NCT06362330
Multi-parametric MRI in Patients of Bladder Cancer
trial testing magnetic resonance imaging in Muscle-invasive Bladder Cancer in 1,000 participants. Currently enrolling.
30 May 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital with Nanjing Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 July 2021 |
| Primary completion | 30 May 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- magnetic resonance imaging
Conditions studied
- Muscle-invasive Bladder Cancer — all drugs for Muscle-invasive Bladder Cancer →
- Artificial Intelligence — all drugs for Artificial Intelligence →
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Who can join
Eligibility, any sex, with Muscle-invasive Bladder Cancer or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive bladder cancer with multiparametric magnetic resonance imaging(MRI).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06362330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of magnetic resonance imaging
Trials testing the same drug.
- NCT05246241 — Preoperative Magnetic Resonance Imaging Abnormalities Predictive of Lumbar Herniation Recurrence · completed
- NCT06849063 — Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE · recruiting
- NCT06526442 — MRE for Diagnosis of Pancreatic Masses · recruiting
- NCT04409457 — Self-Control in Bulimia Nervosa · NA · completed
- NCT05132959 — The Morphometric Parameters of Shoulder and Supraspinatus Tendinosis · completed
Other recruiting trials for Muscle-invasive Bladder Cancer
Currently open trials in the same condition.
- NCT07475806 — A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep · Phase 2 · recruiting
- NCT06682728 — Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence · Phase 2 · recruiting
- NCT04660344 — A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer · Phase 3 · active not recruiting
Other The First Affiliated Hospital with Nanjing Medical University trials
Trials by the same sponsor.
- NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
- NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
- NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
- NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06362330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
- Last refreshed: 12 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing